Men harboring BRCA2 or MMR mutations may benefit from earlier prostate-specific antigen (PSA) testing or colonoscopic screening, whereas azoospermic men with Y-chromosome deletions could undergo periodic testicular ultrasonography and serum tumor-marker assessment. The gene discussed is KLK3; the disease is neoplasm.